journal
https://read.qxmd.com/read/38742390/interventions-aiming-to-improve-advance-care-planning-uptake-in-oncology-a-scoping-review-of-recent-randomized-controlled-trials
#1
JOURNAL ARTICLE
Yves Libert, Caroline Langhendries, Lisa Choucroun, Isabelle Merckaert
PURPOSE OF REVIEW: The evidence regarding the effectiveness of interventions aiming to improve ACP uptake appears mixed. The purpose of this scoping review is to summarize findings from recent RCTs assessing the efficacy of interventions designed to increase ACP uptake in cancer care. RECENT FINDINGS: The PubMed database was searched for studies published between 2021 and 2023. Ten RCTs were identified that evaluated a wide range of interventions aimed at encouraging or facilitating ACP communication among patients with advanced cancer, caregivers, and HCPs...
May 10, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38726846/active-surveillance-and-emerging-medical-treatment-options-for-desmoid-when-and-for-whom
#2
JOURNAL ARTICLE
Sylvie Bonvalot, Aisha Miah, Bernd Kasper
PURPOSE OF REVIEW: This article discusses the evolving approaches to desmoid tumors management, shedding light on recent developments. RECENT FINDINGS: Active surveillance has become the primary approach for managing primary peripheral desmoid tumors. This strategy was initially based on evidence from retrospective studies. Roughly 50% of cases managed with active surveillance show spontaneous stabilization or regression. Recent prospective trials conducted in Italy, The Netherlands, and France (2022-2023) confirm the efficacy of active surveillance, revealing 3-year progression-free survival rates ranging from 53...
May 8, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38726840/new-targeted-therapies-in-liposarcoma-state-of-art-and-future-perspectives
#3
JOURNAL ARTICLE
Andrea Franza, Chiara Fabbroni, Sandro Pasquali, Paolo Giovanni Casali, Roberta Sanfilippo
PURPOSE OF REVIEW: Liposarcomas (LPSs) represent the most common soft tissue sarcoma (STS) subtype, and exhibit distinct clinical molecular features according to histological subgroup. Chemotherapy (ChT), and in particular anthracycline-based schedules, still remains the standard of treatment for all LPS forms. However, given the increasing knowledge gained throughout last years about LPS molecular biology and their genomic profiling, new therapeutic alternatives with targeted drugs are now to be considered...
May 8, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38726837/state-of-the-art-and-trends-in-fibroblast-growth-factor-receptor-directed-therapies-in-gastro-intestinal-malignancies
#4
JOURNAL ARTICLE
Charlotte Hanssens, Oumnia Mouna, Michel Meyers, Alain Hendlisz
PURPOSE OF REVIEW: This review is timely and relevant due to the increasing recognition of the significance of the fibroblast growth factor receptor (FGFR) family in cancer biology. Understanding the role of FGFRs and their dysregulation in various cancers is crucial for developing targeted therapies and improving patient outcomes. RECENT FINDINGS: The review highlights the importance of the FGFR family in cellular processes such as growth, proliferation, and survival...
May 8, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38726843/state-of-the-art-and-upcoming-trends-in-her2-directed-therapies-in-gastrointestinal-malignancies
#5
JOURNAL ARTICLE
Jaeyop Lee, Geoffrey Ku
PURPOSE OF REVIEW: This review critically evaluates the evolution and current status of human epidermal growth factor receptor 2 (HER2)-directed therapies in upper gastrointestinal (GI) malignancies, a timely and relevant inquiry given the dynamic shifts in therapeutic strategies over the past decade. Initial enthusiasm following the Trastuzumab for Gastric Cancer (ToGA) study's demonstration of trastuzumab's efficacy, however, encountered hurdles due to subsequent trials showing limited progress, underscoring the necessity for a reevaluation of therapeutic approaches and the exploration of novel agents...
May 2, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38726845/combination-treatment-with-pd1-pdl-1-inhibitors-for-sarcomas-state-of-the-art-next-questions
#6
JOURNAL ARTICLE
Javier Martin-Broto, Nadia Hindi, David S Moura
PURPOSE OF REVIEW: Only a small fraction of sarcomas exhibit recognized parameters of immune sensitivity, such as tumor mutational burden, PDL-1 expression, or microsatellite instability. Combined strategies aimed to modulate tumor microenvironment to increase the efficacy of PD1/PDL-1 inhibitors in sarcoma. Most explored prospective studies were based on combinations of PD1/PDL-1 inhibitors with antiangiogenics, other immune checkpoints, or chemotherapy. RECENT FINDINGS: Results on 6-month PFS rate, median PFS, and ORR in trials using PD1/PDL-1 inhibitors plus antiangiogenics ranged respectively as 46...
May 1, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38726834/sarculator-how-to-improve-further-prognostication-of-all-sarcomas
#7
JOURNAL ARTICLE
Alessandra Borghi, Alessandro Gronchi
PURPOSE OF REVIEW: Prognostication of soft tissue sarcomas is challenging due to the diversity of prognostic factors, compounded by the rarity of these tumors. Nomograms are useful predictive tools that assess multiple variables simultaneously, providing estimates of individual likelihoods of specific outcomes at defined time points. Although these models show promising predictive ability, their use underscores the need for further methodological refinement to address gaps in prognosis accuracy...
May 1, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38726812/sarcoma-incidence-worldwide-regional-differences-in-histology-and-molecular-subtypes
#8
JOURNAL ARTICLE
Ming-Jing Lee, Tom Wei-Wu Chen
PURPOSE OF REVIEW: There are numerous sarcoma subtypes and vary widely in terms of epidemiology, clinical characteristics, genetic profiles, and pathophysiology. They also differ widely between ethnic groups. This review focuses on the different incidence rates of sarcomas in different regions and the potential explanations for these disparities. RECENT FINDINGS: In an intercontinental study using national cancer registry databases from France and Taiwan, the French population had a higher risk of liposarcomas, leiomyosarcomas, and synovial sarcomas, whereas the Taiwanese population had a higher incidence of angiosarcomas and malignant peripheral nerve sheath tumors...
April 26, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38726797/state-of-the-art-and-upcoming-trends-in-claudin-directed-therapies-in-gastrointestinal-malignancies
#9
JOURNAL ARTICLE
Jane E Rogers, Jaffer A Ajani
PURPOSE OF REVIEW: Claudins, components of tight cell junctions in epithelial and endothelial cells, have emerged as a therapeutic target in gastrointestinal (GI) malignancies, particularly claudin 18.2 (CLDN18.2). RECENT FINDINGS: Zolbetuximab, a chimeric anti-CLDN18.2 monoclonal antibody (mAb), is currently under FDA review and may emerge as the first claudin targeted therapy approved. Phase 3 trials show that zolbetuximab in combination with front-line fluoropyrimidine plus oxaliplatin improves survival in advanced CLDN18...
April 24, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38726828/state-of-the-art-and-upcoming-trends-in-ras-directed-therapies-in-gastrointestinal-malignancies
#10
JOURNAL ARTICLE
Pieterjan Vanclooster, Sofie Seghers, Hans Prenen
PURPOSE OF REVIEW: Overall, the review underscores the evolving landscape of KRAS-targeted therapy and the potential for these approaches to improve outcomes for patients with gastrointestinal malignancies. It highlights the importance of ongoing research and clinical trials in advancing precision medicine strategies for KRAS-driven cancers. This review provides a comprehensive overview of the RAS signaling pathway and its significance in gastrointestinal malignancies. RECENT FINDINGS: The introduction of KRAS inhibitor represents a significant advancement in the treatment landscape for KRAS-mutant cancers...
April 22, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38726808/monitoring-advanced-gastrointestinal-stromal-tumor-with-circulating-tumor-dna
#11
JOURNAL ARTICLE
David Gómez-Peregrina, Carlo Maria Cicala, César Serrano
PURPOSE OF REVIEW: This review explores the role of circulating tumor (ct)DNA as a biomarker for clinical decision-making and monitoring purposes in metastatic gastrointestinal stromal tumor (GIST) patients. We discuss key insights from recent clinical trials and anticipate the future perspectives of ctDNA profiling within the clinical landscape of GIST. RECENT FINDINGS: The identification and molecular characterization of KIT/platelet-derived growth factor receptor alpha (PDGFRA) mutations from ctDNA in metastatic GIST is feasible and reliable...
April 22, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38726807/a-new-comprehensive-and-stratified-concept-for-supportive-care-in-cancer-patients
#12
JOURNAL ARTICLE
Jean Klastersky, Isabelle Libert, Yves Libert, Marie-Aline Echterbille
PURPOSE OF THE REVIEW: Supportive care in oncology has evolved alongside effective anticancer treatments since the 1960s, beginning with the advent of chemotherapy for acute leukemia. It was initially focused on managing treatment-induced complications, and expanded to address broader aspects of patient well being; the scope of supportive care needs to be periodically re-assessed. RECENT FINDINGS: Early palliative care interventions, and more recently advance care planning emerged as vital components, improving patient outcomes and quality of life...
April 15, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38506408/advances-in-testing-for-human-papillomavirus-mediated-head-and-neck-cancer
#13
JOURNAL ARTICLE
Hisham Mehanna, Laia Alemany, Christian von Buchwald
PURPOSE OF REVIEW: New evidence has recently emerged regarding the utility and benefits of dual p16INKa (p16) and Human papillomavirus (HPV) status testing when determining the diagnosis and prognosis of patients with oropharyngeal cancer. RECENT FINDINGS: HPV RNA polymerase chain reaction (PCR) is the most accurate diagnostic test. The other assays (HPV DNA PCR, HPV DNA/RNA in-situ hybridization (ISH) and p16) applied to formalin fixed tumour tissue have varying but high sensitivities and specificities...
March 20, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38441194/molecular-and-nutritional-markers-in-head-and-neck-cancer
#14
JOURNAL ARTICLE
Gerard Milano, Jocelyn Gal, René-Jean Bensadoun
PURPOSE OF REVIEW: There is still a need of biomarkers in the induction and neoadjuvant settings for squamous cell carcinoma of the head and neck (SCCHN). The objective of this concise review article is to give an overview on both predictive and prognostic biomarkers potentially useful for the management of SCCHN. RECENT FINDINGS: Human papilloma virus (HPV) positivity translated by the presence of the protein indicator p16 is synonymous of favorable prognosis SCCHN...
March 1, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38573209/targeting-androgen-biosynthesis-in-prostate-cancer-implications-on-endocrine-physiology
#15
REVIEW
Ghazal Kango, Rana Malek, Heather Mannuel, Arif Hussain
PURPOSE OF REVIEW: Targeting specific steroidogenic enzymes is effective in decreasing testosterone synthesis, resulting in significant antitumor effects in prostate cancer. Such treatments result in disruptions of complicated and intertwining pathways with systemic physiologic consequences via effects on the adrenal gland and renin-angiotensin-aldosterone axis. This review highlights some of these aspects that need to be taken into consideration when treating patients with androgen biosynthesis inhibitors...
May 1, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38573208/special-populations-in-metastatic-renal-cell-carcinoma
#16
JOURNAL ARTICLE
Taylor Goodstein, Ilana Goldberg, Yusuf Acikgoz, Elshad Hasanov, Ramaprasad Srinivasan, Eric A Singer
PURPOSE OF REVIEW: This review focuses on special populations poorly represented in current evidence-based practice for metastatic renal cell carcinoma (mRCC). This includes the elderly and frail, patients on immunosuppression or with autoimmune diseases, patients with brain, liver, and/or bone metastases, and RCC with sarcomatoid features. RECENT FINDINGS: Certain populations are poorly represented in current trials for mRCC. Patients with central nervous system (CNS) metastases are often excluded from first-line therapy trials...
May 1, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38573207/highlighting-recent-progress-in-the-treatment-of-men-with-advanced-prostate-cancer
#17
REVIEW
Theodore Gourdin
PURPOSE OF REVIEW: This review is designed to highlight recent research efforts to optimize treatment strategies in men with advanced prostate cancer. RECENT FINDINGS: Recent research analyses have suggested an overall survival advantage to treating some men with newly identified metastatic prostate cancer with a "triplet" of androgen deprivation therapy, docetaxel, and an androgen receptor axis-targeted agent (ARAT), but further work remains to refine which men need this aggressive of a treatment approach...
May 1, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38573206/current-outstanding-challenges-in-germ-cell-tumors
#18
REVIEW
Tareq Salous, Nabil Adra
PURPOSE OF REVIEW: Despite the remarkable advances in the treatment of germ cell tumors (GCT), several challenges remain. This review aims to highlight some of these challenges and provide guidance on how to navigate through them. RECENT FINDINGS: Patients with International Germ Cell Cancer Collaborative Group poor risk disease have worse prognosis and investigating novel therapeutic interventions are warranted in this population. Patients with brain metastases require a multidisciplinary approach by a group of clinicians experienced in the management of germ cell tumors...
May 1, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38573205/biochemically-recurrent-prostate-cancer-in-the-era-of-embark-and-psma-pet-imaging-everything-has-changed-except-the-patients
#19
REVIEW
David J Einstein, Jeanny B Aragon-Ching, Fatima Karzai, Ravi A Madan
PURPOSE OF REVIEW: Patients with biochemically recurrent prostate cancer (BCR) after unsuccessful curative therapies frequently have an indolent and asymptomatic disease course for years. There are no prospective data showing that treating BCR improves overall survival despite new imaging strategies and emerging therapeutic data. Managing BCR requires a unique perspective in oncology that balances toxicities and disease kinetics. RECENT FINDINGS: Prostate specific membrane antigen (PSMA) imaging is now widely available and can define subclinical disease in patients with BCR who otherwise have negative CT and bone scans, but limited data exists showing that treating PSMA-positive disease has long term impact...
May 1, 2024: Current Opinion in Oncology
https://read.qxmd.com/read/38573204/organ-preservation-in-muscle-invasive-urothelial-bladder-cancer
#20
REVIEW
Scot A Niglio, Juhi M Purswani, Peter B Schiff, Jonathan W Lischalk, William C Huang, Katie S Murray, Andrea B Apolo
PURPOSE OF REVIEW: The most common definitive treatment for muscle-invasive bladder cancer (MIBC) is radical cystectomy. However, removing the bladder and surrounding organs poses risks of morbidity that can reduce quality of life, and raises the risk of death. Treatment strategies that preserve the organs can manage the local tumor and mitigate the risk of distant metastasis. Recent data have demonstrated promising outcomes in several bladder-preservation strategies. RECENT FINDINGS: Bladder preservation with trimodality therapy (TMT), combining maximal transurethral resection of the bladder tumor, chemotherapy, and radiotherapy (RT), was often reserved for nonsurgical candidates for radical cystectomy...
May 1, 2024: Current Opinion in Oncology
journal
journal
30435
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.